 - Must have participated in Study 215ON201 and received at least 1 dose of BIIB033 or placebo, as per protocol, within 2 years 4 months from Day 1 of this study 2 years from Week 32 or projected Week 32 visit, if the subject did not complete all visits in Study 215ON201. 